Full Year 2024 Inventiva SA Earnings Call Transcript
Key Points
- Inventiva SA (IVEVF) made significant progress in the clinical development of lanifibranor, closing screening for Phase 3 NATiV3 early in January 2025.
- The company received positive recommendations from three data monitoring committee meetings to continue the NATiV3 trial without modifications.
- Inventiva SA (IVEVF) reinforced its clinical data set for lanifibranor with positive results from the LEGEND trial, showing significant improvements in HbA1c and liver injury markers.
- The company successfully raised approximately $184 million in gross proceeds through various financing operations, strengthening its financial position.
- Inventiva SA (IVEVF) expanded its governance by appointing experienced board members, including Mark Pruzanski, enhancing its strategic capabilities.
- Inventiva SA (IVEVF) decided to halt all preclinical activities not related to lanifibranor, resulting in a workforce reduction of approximately 50%.
- The company reported a net loss of $184.2 million for the full year 2024, compared to $110.4 million in 2023.
- R&D expenses decreased by 17% in 2024 due to operational delays, impacting the company's development timeline.
- The company faces potential challenges in securing additional financing to support its long-term objectives beyond the current cash runway.
- Inventiva SA (IVEVF) needs to manage the potential weight gain associated with lanifibranor, which may require combination treatments to mitigate this side effect.
Good morning. Good afternoon, everyone. Thank you for joining us to discuss our 2024 full-year financial results. We issued the full-year press release this morning and the webcast that will be available in the Investor section of our website. I want to remind everyone that various statements that we may make today during this conference call and during the Q&A session will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Joining me on this call is Jean Volatier, our Chief Financial Officer; and Pierre Broqua, CSO and Co-Founder. I will first go some of the key highlights for 2024 and some recent updates of our activities before I leave the floor to Jean, who go over the full-year financial results. And of course, we'll have some time at the end of the call for a Q&A.
So on the highlight for '24, so '24 was ended on a very positive note, and we started 2025 strong, ready, and enthusiastic for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
